First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Agency memo on manufacturer communications about unapproved uses says new court rulings and studies on off-label uses and adverse reactions support restrictions; whether agency’s new leadership has the same view remains to be seen.
You may also be interested in...
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.
For now, FDA is using a case-by-case approach for reviewing and approving expanded access applications asking for off-label uses.
With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.